Management of unspecified anxiety disorder: Expert consensus.
Hitoshi SakuraiKen InadaYumi AokiMasahiro TakeshimaKenya IeMorito KiseEriko YoshidaTakashi TsuboiHisashi YamadaHikaru HoriYasushi InadaEiji ShimizuKazuo MishimaKoichiro WatanabeYoshikazu TakaesuPublished in: Neuropsychopharmacology reports (2023)
The field experts recommend that benzodiazepine anxiolytics should not be used as a first-line option for patients with unspecified anxiety disorder. Instead, several nonpharmacological interventions and switching to SSRIs were endorsed for the primary treatment of unspecified anxiety disorder and as alternatives to benzodiazepine anxiolytics.
Keyphrases